Patient advocacy groups play many roles in orphan drug development, including funding and propelling early development and interacting with key stakeholders such as the patients, their caregivers, regulatory bodies, elected officials, and payers. By engaging with these organizations throughout the drug development process, drug developers may have a smoother development path and be able to launch new therapies for these rare diseases faster.
How do patient advocacy groups support research & development efforts in the rare disease space? How can biopharma companies support these endeavors?
How do patient advocacy groups interact with key industry stakeholders?
How can biopharma companies support nascent advocacy groups, and how should they engage established organizations?